Clinical implications of stopping nevirapine-based antiretroviral therapy: Relative pharmacokinetics and avoidance of drug resistance

HIV Medicine

Volumn 5, Issue 3, 2004, Pages 180-184

  Mackie, N E ^a   Fidler, S ^a   Tamm, N ^a   Clarke, J R ^a   Back, D ^b   Weber, J N ^a   Taylor, G P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Drug resistance; Navirapine; Pharmacokinetics; Stopping therapy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MALE; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; PREDICTION; PRIORITY JOURNAL; VIRUS LOAD; WILD TYPE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 2942674438     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00208.x     Document Type: Article

References (8)

1. Havlir D, Cheeseman SH, McLaughlin M et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-545.
2. de Jong MD, Vella S, Carr A et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-intected persons does not result in sustained suppression of viral replication. J Infect Dis 1997; 175: 966-970.
3. Eshleman SH, Mracna M, Guay LA et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-1957.
4. Cunningham CK, Chaix ML, Rekacewicz C et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intraparturn nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186: 181-188.
5. Fidler S, Oxenius A, Brady M et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 2049-2054.
6. Mofenson LM. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5118a1.htm. 2002.
7. Gibbons SE, Reynolds ME, Lloyd J et al. Efavirenz and nevirapine: possible candidates for therapeutic drug monitoring (TDM) in clinical practice. HIV Med 2002; 3: 163-164.
8. Hance AJ, Lemiale V, Izopet J et al. Changes in human immunodeficiency virus type 1 populations after treatment interruptions in patients failing antiretroviral therapy. J Virol 2001; 57: 6410-6417.